A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido lung cancer clinical study group trial (HOT) 0901

Toshiyuki Harada, Satoshi Oizumi, Kenichiro Ito, Kei Takamura, Eiki Kikuchi, Tomoya Kuda, Shunichi Sugawara, Aya Suzuki, Makoto Maemondo, Yuka Fujita, Ichiro Kinoshita, Akira Inoue, Fumihiro Hommura, Yutaka Katsuura, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Amrubicin, a third-generation synthetic anthracycline agent, has favorable clinical activity and acceptable toxicity for the treatment of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer. We conducted this study to evaluate the efficacy and safety of amrubicin for advanced NSCLC patients as a third- or fourth-line therapy. Eligible patients had recurrent or refractory advanced NSCLC after second- or third-line therapy. Patients received amrubicin, 35 mg/m2 i.v. on days 1-3 every 3 weeks. The primary endpoint was the disease control rate (DCR). Secondary endpointswerethe overall survival (OS) time, progression-free survival (PFS) time, response rate, and toxicity profile. Of the 41 patients enrolled, 26 received amrubicin as a third-line and 15 received it as a fourth-line therapy. The median number of treatment cycles was two (range, 1-9). Objective responses were complete response (n = 0), partial response (n = 4), stable disease (n = 21), progressive disease (n=15), and not evaluable (n1), resulting in a DCR of 61.0% (95% confidence interval, 46.0%-75.9%). The overall response rate was 9.8% (95% confidence interval, 0.6%-18.8%). The median PFS interval was 3.0 months, median OS time was 12.6 months, and 1-year survival rate was 53.7%. Grade 3 or 4 hematological toxicities were neutropenia (68%), anemia (12%), thrombocytopenia (12%), and febrile neutropenia (17%). Nonhematological toxicities were mild and reversible. No treatment-related deaths were observed. Amrubicin showed significant clinical activity with manageable toxicities as a third- or fourth-line therapy for patients with advanced NSCLC. This study provides relevant data for routine practice and future prospective trials evaluating third- or fourth-line treatment strategies for patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)439-445
Number of pages7
JournalOncologist
Volume18
Issue number4
DOIs
Publication statusPublished - 2013

Keywords

  • Amrubicin
  • Chemotherapy
  • Fourth line
  • Non-small cell lung cancer
  • Third line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido lung cancer clinical study group trial (HOT) 0901'. Together they form a unique fingerprint.

Cite this